Complete Genomics and Illumina reach mutual settlement
Mountain View | 19 July 2013

Sequencing company Illumina has settled two patent infringement suits brought against BGI-owned rival Complete Genomics, with the companies agreeing that no payments will be made between them.

The settlement was announced by Complete Genomics in a public release on 18 July.

The first of the cases settled was brought by Illumina in 2010 and concerned three patents (US6306597, US7232656 and US7598035) describing DNA-sequencing techniques which, Illumina claimed, were included in Complete Genomics’ sequencing technology without permission.

The second case was brought in 2012, concerning another patent (US8192930) which Illumina claimed was infringed in the same piece of Complete Genomics.

As of 18 July, the companies have entered into mutual releases, agreeing to bear their own costs for the dispute to date. No licenses have been issued by Illumina as part of the settlement, according to the release.

Clifford Reid, CEO of Complete Genomics, said: "We are pleased to have reached a settlement with Illumina regarding this matter. This resolution allows Complete to focus on its vision of revolutionizing medicine through the use of whole genome sequencing."

Illumina did not respond immediately to a request for comment.

Complete Genomics was acquired by BGI in March.

Author: Carri Swann

More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization